No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel

Bregt S. Kappelhoff, Alwin D.R. Huitema, Albert T.A. Mairuhu, Jan H.M. Schellens, Jos H. Beijnen

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction. Plasma concentrations of nevirapine (dose: 200 mg twice daily orally) and paclitaxel (dose: 100 mg/m2 3-h i.v. infusion) were determined in a HIV-1-infected patient with Kaposi's sarcoma. Since both drugs are metabolized via the same cytochrome P450 isoenzymes, investigation of a drug-drug interaction was considered important. We found that the plasma concentrations of nevirapine given together with paclitaxel were similar to those given without paclitaxel. The exposures to paclitaxel (AUC0-∞ = 3787 h·ng/ml) and its hydroxy metabolites when co-administered with nevirapine were comparable to the mean exposure to paclitaxel and its metabolites from eight historical controls (AUC0-∞ = 3614 h·ng/ml) treated with the same dose. No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel could be demonstrated in our HIV-1-infected patient.

Original languageEnglish
Pages (from-to)627-630
Number of pages4
JournalAnti-Cancer Drugs
Issue number6
Publication statusPublished - Jul 2005
Externally publishedYes


  • Drug-drug interaction
  • Nevirapine
  • Paclitaxel
  • Pharmacokinetics


Dive into the research topics of 'No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel'. Together they form a unique fingerprint.

Cite this